ORLANDO, Fla.--(BUSINESS WIRE)--New data released today at the 2009 American College of Cardiology meeting demonstrated exceptional long-term safety and effectiveness results for the Endeavor drug-eluting coronary stent from Medtronic, Inc. (NYSE:MDT), in a large multicenter, real-world study, in which no defined patient selection criteria were specified, and angioplasty was used at medical discretion. Two-year results for more than 2,000 patients in the international, E-Five study show that the Endeavor stent was associated with a low rate of both overall (0.7 percent) and very late stent thrombosis (VLAST) at 0.1 percent.
